{"success":true,"data":{"pressRelease":{"id":"84547","rtpr_id":"nGNXsVkS8","ticker":"DARE","exchange":"NASDAQ","all_tickers":["DARE"],"title":"Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event","author":"Globe Newswire","published_at":"2026-07-09T12:43:00.097Z","article_body":"Live video webcast on Tuesday, July 14(th), at 4:00 PM ET\nRegister here\n(https://www.globenewswire.com/Tracker?data=kD9xlV7QZ0Q-oHWMADRpp6yZgUAohGtsa9Qmns9mo1QPlBEI03jOdvuvNe8EsfBFGPdRw7T6TGZ69nmz0P2hJBMfTqFbpxXmPueNhYLmydOhYRGLt-kNinwETtV2Vt5DnzPiPmd8AqX7dMgbFajW5g==)\n\nSAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:\nDARE), a purpose-driven health biotech company solely focused on closing the\ngap in women's health between promising science and real-world solutions,\ntoday announced that it will participate in a Virtual Investor Closing Bell\n(https://www.globenewswire.com/Tracker?data=It8otvHNJbofY8OhlFckeScWeUT2S9iRwdiCNeG92fAVHAqFB2xZOeBWkHhebZknnyDhwpz04J0geGmzTRZsqRl9sE0_ZHWNZhzF25y-Fr2pn2fs70dCPj3uaXbHRe3oLpi6SViC3Ic_aCEXYpMcWoOzz0TYZXuNJ9Blg8AeWbg=)\nevent on Tuesday, July 14, 2026, at 4:00 PM ET.\n\nFor the segment, Sabrina Martucci Johnson, President and Chief Executive\nOfficer\n(https://www.globenewswire.com/Tracker?data=q-15JC3leebqYvLo_dlUp6w_r9vDArXC5obHwcx2zeZE484aMu7t1_vQ5r_LOiqsYtnpX0-mtkxLHkXXT51CT2I8Gk1PyJjpDyMlb1sB3Z3gaw9oGjmTxLkXDIwglZfj_v5hjs4vl1QY7VBr8AIo3AzgiGKabP_q23SduaiA7Pt-KPEjBG1ztdxp-xmpHxX40tlZvS--_eVomtV8pFAfGw==)\nof Daré Bioscience, will provide a brief corporate overview highlighting the\nrecent launch of FloraSync LF5™, the Company's strategy for thoughtfully\nbuilding its commercial business while advancing its differentiated women's\nhealth pipeline, and the milestones that will shape Daré's long-term growth.\nThe discussion will also provide insight into the Company's disciplined\napproach to capital allocation, commercialization, and execution as it works\nto create sustainable value for shareholders.\n\nAdditionally, there will be a live question and answer session with audience\nparticipants. Ms. Martucci Johnson will answer as many questions as possible\nin the time allowed.\n\nA live video webcast\n(https://www.globenewswire.com/Tracker?data=WmSXE5E8CNP-bi-ABbhyL5evx5YZ8lQ-6uMevfBa5dF-3mAmyjMD4Rh3R56X5rtqqisXFjqMIayKilb68OWT6P-Y_3eOldGfiMuoSFmFRx1LskhUfb8Kx9lXFV83a5TPvo5Y2XSGoS5rsGeE5zRplR72MTHpPTNE2B-Sm46hbZQ=) will\nbe available on the Presentations, Events & Webcasts\n(https://www.globenewswire.com/Tracker?data=MABVE22hTv6qQiVsriMtfQjGAnN8iNpDcR9y-ss1zyYBLcdvqApevvO7YxWOetprvdMhNsakq4Ogq8_jIww9_4YsbjadfdbmSVg0r2o3MuUFB7vs7z_XY-Jz3bV1OPuuH8vD3OZI5ox_eI6G0K570X9ylzx15TalOFO9dtLZWYQ=) page\nof the Investors section\n(https://www.globenewswire.com/Tracker?data=kdNxP3nfGUHibdHGxXZfTntjBfXyVypms9x579cqrMm4dbU2kAQvlGdHuUeFzhZ969d2VAD9RY1Stgp5FA14EBi-efIfky1bOxToy4kFiCk=)\nof the Company’s website (darebioscience.com\n(https://www.globenewswire.com/Tracker?data=Vxtwy2BMchPj48mkS6vkthbeljP8xNUBuIii3g7oUNT9c6xFRKvJe8LHWt3kTmzHfXuOfVXQT4p0uzy3uyCwE92b4ThvTjkcrnxSlesLpaU=)).\nA webcast replay will become available approximately two hours following the\nlive event and will be accessible in the same section of the Company’s\nwebsite for 90 days.\n\nABOUT DARÉ BIOSCIENCE, INC.\n\nDaré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company\nsolely focused on closing the gap in women’s health between promising\nscience and real-world solutions. Every innovation Daré advances is based in\nadvanced science and backed by rigorous, peer-reviewed research. From\ncontraception to menopause, sexual health to fertility, vaginal health to\ninfectious disease, Daré is working to close critical gaps in care using\nscience that serves her needs. For decades, women have been told to “wait it\nout” or “live with it,” while innovations that could improve their\nquality of life languish in the regulatory or funding pipeline. With growing\nawareness around menopause, sexual health, and vaginal health, the\nconversation is shifting. However, access to proven solutions is lagging.\nDaré is working to change that. Learn more at darebioscience.com\n(https://www.globenewswire.com/Tracker?data=Vxtwy2BMchPj48mkS6vkth_cirN6FfKqBXGgsvObwA8PxvpvkgTiAUX8uPTfBZSZsONfd-TuBkdGdi26m_uyNcEWipWgj6wDg4VWw_dOub4=).\n\nContact:\nDaré Bioscience Investor Relations\ninnovations@darebioscience.com\nSource: Daré Bioscience, Inc.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/deaaf9ba-24cc-4909-ab8d-1982b8b4e650)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXsVkS8","title":"Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event","author":"Globe Newswire","ticker":"DARE","created":"2026-07-09T12:43:00.097Z","tickers":["DARE"],"exchange":"NASDAQ","article_body":"Live video webcast on Tuesday, July 14(th), at 4:00 PM ET\nRegister here\n(https://www.globenewswire.com/Tracker?data=kD9xlV7QZ0Q-oHWMADRpp6yZgUAohGtsa9Qmns9mo1QPlBEI03jOdvuvNe8EsfBFGPdRw7T6TGZ69nmz0P2hJBMfTqFbpxXmPueNhYLmydOhYRGLt-kNinwETtV2Vt5DnzPiPmd8AqX7dMgbFajW5g==)\n\nSAN DIEGO, July 09, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:\nDARE), a purpose-driven health biotech company solely focused on closing the\ngap in women's health between promising science and real-world solutions,\ntoday announced that it will participate in a Virtual Investor Closing Bell\n(https://www.globenewswire.com/Tracker?data=It8otvHNJbofY8OhlFckeScWeUT2S9iRwdiCNeG92fAVHAqFB2xZOeBWkHhebZknnyDhwpz04J0geGmzTRZsqRl9sE0_ZHWNZhzF25y-Fr2pn2fs70dCPj3uaXbHRe3oLpi6SViC3Ic_aCEXYpMcWoOzz0TYZXuNJ9Blg8AeWbg=)\nevent on Tuesday, July 14, 2026, at 4:00 PM ET.\n\nFor the segment, Sabrina Martucci Johnson, President and Chief Executive\nOfficer\n(https://www.globenewswire.com/Tracker?data=q-15JC3leebqYvLo_dlUp6w_r9vDArXC5obHwcx2zeZE484aMu7t1_vQ5r_LOiqsYtnpX0-mtkxLHkXXT51CT2I8Gk1PyJjpDyMlb1sB3Z3gaw9oGjmTxLkXDIwglZfj_v5hjs4vl1QY7VBr8AIo3AzgiGKabP_q23SduaiA7Pt-KPEjBG1ztdxp-xmpHxX40tlZvS--_eVomtV8pFAfGw==)\nof Daré Bioscience, will provide a brief corporate overview highlighting the\nrecent launch of FloraSync LF5™, the Company's strategy for thoughtfully\nbuilding its commercial business while advancing its differentiated women's\nhealth pipeline, and the milestones that will shape Daré's long-term growth.\nThe discussion will also provide insight into the Company's disciplined\napproach to capital allocation, commercialization, and execution as it works\nto create sustainable value for shareholders.\n\nAdditionally, there will be a live question and answer session with audience\nparticipants. Ms. Martucci Johnson will answer as many questions as possible\nin the time allowed.\n\nA live video webcast\n(https://www.globenewswire.com/Tracker?data=WmSXE5E8CNP-bi-ABbhyL5evx5YZ8lQ-6uMevfBa5dF-3mAmyjMD4Rh3R56X5rtqqisXFjqMIayKilb68OWT6P-Y_3eOldGfiMuoSFmFRx1LskhUfb8Kx9lXFV83a5TPvo5Y2XSGoS5rsGeE5zRplR72MTHpPTNE2B-Sm46hbZQ=) will\nbe available on the Presentations, Events & Webcasts\n(https://www.globenewswire.com/Tracker?data=MABVE22hTv6qQiVsriMtfQjGAnN8iNpDcR9y-ss1zyYBLcdvqApevvO7YxWOetprvdMhNsakq4Ogq8_jIww9_4YsbjadfdbmSVg0r2o3MuUFB7vs7z_XY-Jz3bV1OPuuH8vD3OZI5ox_eI6G0K570X9ylzx15TalOFO9dtLZWYQ=) page\nof the Investors section\n(https://www.globenewswire.com/Tracker?data=kdNxP3nfGUHibdHGxXZfTntjBfXyVypms9x579cqrMm4dbU2kAQvlGdHuUeFzhZ969d2VAD9RY1Stgp5FA14EBi-efIfky1bOxToy4kFiCk=)\nof the Company’s website (darebioscience.com\n(https://www.globenewswire.com/Tracker?data=Vxtwy2BMchPj48mkS6vkthbeljP8xNUBuIii3g7oUNT9c6xFRKvJe8LHWt3kTmzHfXuOfVXQT4p0uzy3uyCwE92b4ThvTjkcrnxSlesLpaU=)).\nA webcast replay will become available approximately two hours following the\nlive event and will be accessible in the same section of the Company’s\nwebsite for 90 days.\n\nABOUT DARÉ BIOSCIENCE, INC.\n\nDaré Bioscience (NASDAQ: DARE) is a purpose-driven health biotech company\nsolely focused on closing the gap in women’s health between promising\nscience and real-world solutions. Every innovation Daré advances is based in\nadvanced science and backed by rigorous, peer-reviewed research. From\ncontraception to menopause, sexual health to fertility, vaginal health to\ninfectious disease, Daré is working to close critical gaps in care using\nscience that serves her needs. For decades, women have been told to “wait it\nout” or “live with it,” while innovations that could improve their\nquality of life languish in the regulatory or funding pipeline. With growing\nawareness around menopause, sexual health, and vaginal health, the\nconversation is shifting. However, access to proven solutions is lagging.\nDaré is working to change that. Learn more at darebioscience.com\n(https://www.globenewswire.com/Tracker?data=Vxtwy2BMchPj48mkS6vkth_cirN6FfKqBXGgsvObwA8PxvpvkgTiAUX8uPTfBZSZsONfd-TuBkdGdi26m_uyNcEWipWgj6wDg4VWw_dOub4=).\n\nContact:\nDaré Bioscience Investor Relations\ninnovations@darebioscience.com\nSource: Daré Bioscience, Inc.\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/deaaf9ba-24cc-4909-ab8d-1982b8b4e650)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-07-09T12:43:00.198448308Z","server_sent_at_ms":1783600980198},"received_at":"2026-07-09T12:43:00.249Z","source_url":null},"analysis":{"id":"73604","press_release_id":"84547","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Daré Bioscience CEO Sabrina Martucci Johnson will participate in a Virtual Investor Closing Bell event on Tuesday, July 14, 2026, at 4:00 PM ET.\n\nThe segment will feature a corporate overview highlighting the recent launch of FloraSync LF5, the company's commercial strategy, and its women's health pipeline.\n\nA live Q&A session will follow, and a webcast replay will be available on the company's investor relations website for 90 days.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine investor event announcement; no new material data."},"keyFigures":{},"quotedText":"Every innovation Daré advances is based in advanced science and backed by rigorous, peer-reviewed research.","namedEntities":{"people":[{"name":"Sabrina Martucci Johnson","role":"President and Chief Executive Officer"}],"products":["FloraSync LF5"],"companies":[{"name":"Daré Bioscience, Inc.","ticker":"DARE"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"This is a routine announcement of a virtual investor event (Closing Bell). It contains no new financial data, clinical results, or strategic changes. It is standard corporate communications activity."},"tickerRelevance":{"others":[],"primary":"DARE"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"routine_ir_event","sectorWeight":"neutral","householdBrandBoost":0}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Daré Bioscience CEO Sabrina Martucci Johnson will participate in a Virtual Investor Closing Bell event on Tuesday, July 14, 2026, at 4:00 PM ET.\n\nThe segment will feature a corporate overview highlighting the recent launch of FloraSync LF5, the company's commercial strategy, and its women's health pipeline.\n\nA live Q&A session will follow, and a webcast replay will be available on the company's investor relations website for 90 days.","key_figures":{},"named_entities":{"people":[{"name":"Sabrina Martucci Johnson","role":"President and Chief Executive Officer"}],"products":["FloraSync LF5"],"companies":[{"name":"Daré Bioscience, Inc.","ticker":"DARE"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-07-09T12:45:57.324Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"routine_ir_event","sectorWeight":"neutral","householdBrandBoost":0}},"durationMs":19570,"modelName":"george-droid-qwen-72b"}}